AVCT stock near 52-week high as Avacta Group pre|CISION data challenges Enhertu benchmark at AACR 2026

Avacta Group PLC (AIM: AVCT) presented two datasets at the American Association for Cancer Research Annual Meeting 2026 in Philadelphia on 21 April that materially extended the preclinical case for its pre|CISION peptide-drug conjugate platform, with particular focus on AVA6103, its second clinical candidate currently in Phase 1 development. The presentations delivered new pharmacokinetic comparisons positioning AVA6103 favorably against the blockbuster antibody-drug conjugate Enhertu, and introduced the first in vivo efficacy and exposure data for the company’s dual payload program, AVA6207. For a company whose shares have risen approximately 120% over the past year to trade around 77p-78p on the day of the presentations, the AACR disclosures arrive at a moment when scientific momentum must begin translating into clinical proof-of-concept to justify and extend the re-rating.

What does the AVA6103 pharmacokinetic comparison with Enhertu reveal about the pre|CISION delivery advantage?

The centrepiece of the first AACR presentation was a direct pharmacokinetic comparison between AVA6103 and Enhertu, the AstraZeneca and Daiichi Sankyo antibody-drug conjugate that has reshaped the oncology landscape across HER2-positive breast, gastric, and lung cancers. Avacta Group used an AI-generated synthetic comparator arm to recreate a published AstraZeneca dataset and place it alongside experimental AVA6103 data from a comparable FAP-high animal model, with both drugs deploying closely related payloads in the topoisomerase I inhibitor class.

Three metrics emerged from the comparison. AVA6103 demonstrated more rapid tumor penetration and payload release. The tumor maximum concentration achieved with AVA6103 was more than one log higher than the Enhertu comparator, a difference of tenfold or greater that carries direct implications for potential antitumor activity at comparable or lower doses. The Tumor Selectivity Index, calculated as the ratio of tumor drug exposure to plasma drug exposure, came in at three times higher for AVA6103 than for Enhertu. Selectivity is the defining challenge in oncology delivery. A drug that concentrates disproportionately in tumor tissue rather than circulating systemically is, in principle, capable of hitting harder at the tumor while sparing healthy tissue from dose-limiting toxicity. This is the core thesis underpinning the pre|CISION platform and these numbers, if they translate to the clinic, would represent a structurally differentiated pharmacological profile.

The synthetic comparator methodology deserves scrutiny. Using AI to reconstruct a competitor’s published dataset rather than running a head-to-head experiment in a single laboratory avoids batch-to-batch variability concerns but introduces its own uncertainties around data reconstruction fidelity. Avacta Group has not published the full methodology underlying the AI reconstruction, and independent replication will be required before the comparison carries decisive scientific weight. That said, the pre|CISION mechanism of FAP-mediated cleavage at the tumor stroma is mechanistically distinct from the antibody-based delivery of Enhertu, and the pharmacokinetic logic of a small peptide penetrating tumor tissue faster than a large antibody conjugate is sound. The comparison is hypothesis-generating rather than definitive, but it gives the FOCUS-01 Phase 1 trial a clear set of clinical endpoints to target.

How does AVA6103 perform in low-FAP tumor models and what does this mean for addressable patient populations?

A persistent concern in the FAP-targeted oncology space has been the degree to which FAP expression varies across patients and tumor types, and whether drugs dependent on FAP cleavage for payload activation lose potency in tumors with lower FAP levels. The AACR data addressed this directly. AVA6103 demonstrated robust antitumor activity in multiple patient-derived xenograft models with FAP expression ranging from very low to high, with potent effects observed even when FAP was present only in stromal cells at minimal levels.

This is a commercially significant finding. It broadens the potential patient population for AVA6103 beyond the subset of patients with FAP-high tumors that might initially have been considered the primary target. Two indications have been added to the FOCUS-01 trial on the basis of preclinical activity and biomarker data from the collaboration with Tempus: colorectal cancer and hormone receptor-positive breast cancer. Both are large indication categories with substantial unmet need and established patient identification infrastructure, particularly given the breadth of genomic profiling now embedded in oncology centres. Colorectal cancer represents one of the most underserved areas in the antibody-drug conjugate competitive landscape, where Enhertu’s dominance in breast and gastric settings has not yet extended with the same force. If AVA6103 demonstrates activity in CRC patients through FOCUS-01, it occupies a strategically valuable niche.

The first patient was treated in FOCUS-01 in March 2026, and Avacta Group has indicated that an initial clinical data readout is anticipated later this year. That timeline gives retail and institutional investors a defined catalyst window within 2026, which partly explains the share price performance that has compressed the gap toward the 52-week high of 84p.

What does the first in vivo dual payload data for AVA6207 add to the platform valuation case?

The second AACR presentation introduced AVA6207, Avacta Group’s dual payload program, with the first in vivo exposure and efficacy data disclosed publicly. AVA6207 is designed to release two distinct payloads simultaneously through FAP cleavage: a topoisomerase I inhibitor and a DNA Damage Repair inhibitor. The combination is intended to induce synthetic lethality in tumors carrying specific resistance mechanisms to topoisomerase I inhibitor therapy alone.

Two genetic resistance models were tested, tumors harboring ATM-deficiency and tumors with loss of SLFN11, both of which represent clinically relevant mechanisms through which cancer cells evade topoisomerase I inhibitor treatment. AVA6207 demonstrated activity against both models, and in vivo pharmacokinetic data showed tumor-selective release of both payloads with a Tumor Selectivity Index described as highly potent. Antitumor efficacy was demonstrated in a patient-derived xenograft model of HER2-positive gastric cancer with low FAP expression, where AVA6207 outperformed the HER2-targeted comparator Enhertu.

The strategic importance of AVA6207 extends beyond its own clinical prospects. It demonstrates that the pre|CISION platform is not a single-payload architecture but a flexible delivery system capable of co-delivering combinations of mechanistically complementary drugs in a tumor-selective manner. This expands the potential licensing and partnership narrative considerably. A platform that can address resistance mechanisms to one of oncology’s most commercially successful drug classes, while retaining tumor selectivity, is substantially more attractive to a potential acquirer or co-development partner than a platform tied to a single payload modality. The dual payload work is still early, but the in vivo data milestone is the transition from purely in vitro or mechanistic claims to demonstrated pharmacology in animal models with antitumor outcomes.

How does the AVCT share price reflect the scientific progress and what are the key execution risks ahead?

Avacta Group shares were trading at approximately 77p-78p on 21 April 2026, within a 52-week range of 26p to 84p, placing the stock close to its year high on the day of the AACR disclosures. The 120% gain over the prior year has substantially outpaced the FTSE All Share index, and the consensus analyst recommendation is Buy with an average price target of around 79p and a high estimate of 103p. The market has broadly priced in the directional scientific story. What it has not yet priced in with certainty is clinical translation.

The progression from pharmacokinetic superiority in preclinical models to meaningful response rates and a clean safety profile in Phase 1 patients is where the majority of oncology programs fail. FOCUS-01 is enrolling at specialist US centres, and the inclusion of colorectal cancer and HR-positive breast cancer expands both the data generation potential and the patient recruitment pool, but it also means the trial must demonstrate activity across biologically heterogeneous tumor types with different FAP expression patterns. Dose escalation, tolerability, and the first efficacy signals will each represent binary events for the share price in the second half of 2026.

The cash position as of end 2025 was reported at £16.9 million, sufficient to fund near-term operations but not reflective of the capital requirements of an expanded multi-indication Phase 1 program. Avacta Group has previously conducted equity fundraises, including a £16 million oversubscribed placing, and the company’s current re-rating does provide a more favorable equity issuance environment if further capital is needed before partnership revenues materialise. The risk is dilution. At a market capitalisation of approximately £360 million, the company is priced for execution, and any clinical setback or funding announcement at an unfavorable price would compress the valuation rapidly.

The competitive backdrop is not standing still. The antibody-drug conjugate field has attracted extraordinary capital and development resources from the largest pharmaceutical companies globally, including AstraZeneca, Daiichi Sankyo, Pfizer, and Roche. Avacta Group is not competing with their manufacturing scale or commercial infrastructure at this stage, but it is competing for the same scientific credibility, licensing deal terms, and partnering discussions. The AACR data, particularly the pharmacokinetic comparison with Enhertu, is a deliberate effort to locate the pre|CISION platform within the benchmark conversation that the broader industry is having around payload delivery efficiency.

What does the AACR 2026 data mean for Avacta Group, its competitors, and the oncology delivery platform space: Key takeaways

• AVA6103 demonstrated a Tumor Selectivity Index three times higher than Enhertu in a synthetic comparator analysis, with tumor drug concentrations more than tenfold greater, strengthening the pharmacokinetic differentiation narrative for the pre|CISION platform.
• Robust antitumor activity in PDX models with very low FAP expression removes a significant addressable market constraint and supports the addition of colorectal cancer and HR-positive breast cancer to the FOCUS-01 Phase 1 trial.
• The first patient was treated in FOCUS-01 in March 2026, with initial clinical data anticipated in the second half of 2026, creating a defined near-term catalyst window.
• AVA6207 dual payload in vivo data confirms the pre|CISION platform’s capability to co-deliver two mechanistically distinct payloads with tumor selectivity, addressing topoisomerase I inhibitor resistance mechanisms that limit Enhertu’s durability.
• Demonstrating activity in a HER2-positive gastric cancer PDX model where AVA6207 outperformed Enhertu positions Avacta Group within the benchmark competitive conversation in the XDC drug class.
• The synthetic comparator methodology used for the Enhertu pharmacokinetic comparison requires independent validation and should be treated as hypothesis-generating until replicated or confirmed with clinical correlates.
• At approximately 77p-78p and a market capitalisation near £360 million, AVCT is priced for clinical translation. Any Phase 1 tolerability or efficacy signal below expectations carries significant downside risk.
• Cash resources of £16.9 million at end 2025 and a history of equity fundraising suggest that capital management will remain a variable that investors must monitor alongside clinical progress.
• The Tempus biomarker collaboration providing the rationale for indication expansion reflects the growing importance of companion diagnostic infrastructure in differentiating PDC and ADC programs in competitive licensing negotiations.
• For larger pharmaceutical companies evaluating the XDC drug class, the pre|CISION dual payload architecture may represent the most strategically novel element of Avacta Group’s platform, given its potential to address resistance without sacrificing tumor selectivity.